Compare Ginkgo Bioworks Holdings Inc (DNA) vs Zillow Group Inc Class C (Z) Price & Performance

Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.

DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.

Zillow Group (Z) trades at $33.48, down 0.8% on the day, amid mixed technical signals and ongoing securities litigation. The company shows improving fundamentals with Q2 2026 revenue growth of 18% and consecutive earnings beats, though net margins remain thin at 1.96%. Analyst consensus is divided with a $52 price target representing 55% upside potential from current levels.

While Zillow demonstrates operational improvement and strong monetization growth, significant headwinds include multiple class-action lawsuits and bearish technical indicators. The stock offers substantial upside if legal concerns resolve favorably, but near-term volatility persists due to legal overhang and competitive real estate market pressures.